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Abstract
Background: Patients living in more deprived localities have lower cancer survival in England, but the role of
individual health status at diagnosis and the utilisation of primary health care in explaining these differentials has
not been widely considered. We set out to evaluate whether pre-existing individual health status at diagnosis and
primary care consultation history (peri-diagnostic factors) could explain socio-economic differentials in survival
amongst women diagnosed with breast cancer.
Methods: We conducted a retrospective cohort study of women aged 15–99 years diagnosed in England using
linked routine data. Ecologically-derived measures of income deprivation were combined with individually-linked
data from the English National Cancer Registry, Clinical Practice Research Datalink (CPRD) and Hospital Episodes
Statistics (HES) databases. Smoking status, alcohol consumption, BMI, comorbidity, and consultation histories were
derived for all patients. Time to breast surgery was derived for women diagnosed after 2005. We estimated net
survival and modelled the excess hazard ratio of breast cancer death using flexible parametric models. We
accounted for missing data using multiple imputation.
Results: Net survival was lower amongst more deprived women, with a single unit increase in deprivation quintile
inferring a 4.4% (95% CI 1.4–8.8) increase in excess mortality. Peri-diagnostic co-variables varied by deprivation but
did not explain the differentials in multivariable analyses.
Conclusions: These data show that socio-economic inequalities in survival cannot be explained by consultation
history or by pre-existing individual health status, as measured in primary care. Differentials in the effectiveness of
treatment, beyond those measuring the inclusion of breast surgery and the timing of surgery, should be considered
as part of the wider effort to reduce inequalities in premature mortality.
Keywords: Breast neoplasms, Comorbidity, Early diagnosis, Socioeconomic factors, Survival analysis, Primary health
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Background
Patients living in more deprived localities have lower can-
cer survival in England [1–4]. The avoidable mortality as-
sociated with these socio-economic differences is
considerable [5]. There are three potential routes by which
these inequalities might arise [6, 7]: tumour factors (more
aggressive disease, more advanced disease arising from dif-
ferential ease of access and availability of appointments,
and, or screening), patient factors (differential pre-existing
comorbidities, health or nutritional status, leading to less
effective or under-treatment), and health system factors
(differential referral patterns from primary care, or differ-
ential treatment within secondary care).
To date, the relative contribution of these mechanisms
in explaining the persistence of socio-economic differ-
ences in England has focussed on a variety of factors.
These include the examination of patterns of survival by
screening status [8–10], analyses of routine data from sec-
ondary care [11–16] and the equalisation of treatment
[17–19]. The presence of factors measured in primary
health care, such as the presence of other diseases, obesity,
smoking history, alcohol consumption, as well as the total
number of consultations attended by the patient may also
be associated with these inequalities. However, their role
in explaining survival differentials has not been considered
outside our own analysis of screening-eligible women di-
agnosed with breast cancer [20, 21].
In this study, we specifically consider the relative im-
pact of a) pre-existing individual health status (comor-
bidity and detrimental health behaviours) together with
b) primary care consultation history upon socio-
economic patterns in breast cancer survival, using linked
routine cancer registration and primary care data. These
factors represent potentially modifiable factors which
could help to reduce inequalities and avoidable mortality
for women with breast cancer as well as for patients




The English National Cancer Registry (CR) was individu-
ally linked to Clinical Practice Research Datalink ‘GOLD’
(CPRD) which contains data contributed by practices
using Vision® software [22] and Hospital Episodes Statis-
tics (HES) databases. The CR-CPRD linkage took place
on two different occasions: in 2010 for diagnoses 1988–
2004 and in 2016 for diagnoses 2005–2010. Hospital
Episodes Statistics (HES) data were available for the later
period only.
Deprivation
We used ecologically-derived measures of income
deprivation for each woman: quintiles of the 1991
census-based Carstairs index [23] for women diagnosed
1988–1995, and the English Indices of Multiple
Deprivation (IMD) income domain from 1998 onwards
[24]. Although each of these scores use slightly different
underlying variables, they both aim to quantify relative
deprivation by computing a score from the socio-
economic characteristics of very small areas using the
census or routinely collected administrative data (Car-
stairs: car ownership, overcrowding, social class and un-
employment, IMD: receipt of various means-tested
benefits). The areas used for each score are those de-
fined at the UK’s decennial census (EDs in 1991 c.500
persons; LSOAs in 2001 and 2011 c.1500 persons but
designed to be as socially homogenous as possible) and
are the smallest administrative geography available at
any given time point. Deprivation categories were de-
rived from the score temporally closest to each woman’s
date of diagnosis on the basis of her residential address.
Co-variables
We used information from the cancer registry to derive
each woman’s date and age at diagnosis, tumour charac-
teristics and date of death (if applicable). We derived
stage of disease at diagnosis using all relevant available
clinical information [25]. Each women’s individual smok-
ing status (non- or ex-smoker, current smoker), alcohol
consumption status (non-, ex-, current drinker) and
body mass index [26] were extracted from CPRD records
as previously described [20]. The Charlson comorbidity
score [27] was derived from data recorded in the 18-
month period between 2 years to 6 months before diag-
nosis [28] using information from both CPRD and HES
data for patients diagnosed after 2005. The total number,
as well as the number of “breast-related” vs. “not breast-
related” consultations along with the number of referrals
for breast cancer were derived for 18-month period im-
mediately prior to diagnosis. Breast-related symptoms
included any mention of separate breast symptoms,
within the same consultation or reported at different
times, including breast lump, breast pain, skin changes,
discharging bleeding or inverted nipples. We adopted
the conservative approach of considering only consulta-
tions with a doctor (GP), excluding CPRD records relat-
ing to nurse or other practitioner appointments, as well
as all administrative events such as telephone calls, let-
ters, or the issuing of repeat prescriptions. This avoided
potentially recording one symptom more than once, or
inflating a woman’s total number of consultations by the
inclusion of non-clinical events. Time in days from the
last breast-related consultation to diagnosis (as an indi-
cation of time elapsed from referral to diagnosis) was
calculated for all patients and from diagnosis to first
major breast cancer surgery (within 18months, defined
using OPCS-4 codes, the classification used by clinical
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coders within National Health Service) for women diag-
nosed after 2005. A specific category for missing data
was available for stage, and we similarly coded women
as ‘missing’ if no information on smoking, alcohol and
BMI could be obtained. It was not possible to distinguish
the difference between ‘none observed’ and ‘missing in-
formation’ for pre-existing comorbidities, symptoms, re-
ferrals or surgery. For these variables, ‘none recorded’
was assumed to equate to the non-observation of the
relevant factor in primary and secondary care. Multi-
nomial regression (categorical variables) and non-
parametric tests for trend (continuous variables) [29]
were used to assess the differences between deprivation
categories.
Net survival estimation
Net survival is the survival probability the patients
would experience if their only possible cause of
death were breast cancer. It is independent from
other causes of death (expected mortality, which var-
ies in particular by age and deprivation) and reflects
the prognosis of the disease. We estimated net sur-
vival by each co-variable using the non-parametric
Pohar-Perme estimator [30, 31] implemented in stns
[32]: software available for Stata 16 [33]. This is the
most widely used, unbiased estimator of net survival.
Controlling for expected mortality (or its counter-
part, expected survival) required the use of informa-
tion from deprivation-specific life tables for the
general population of England [34]. Survival esti-
mates were derived for all co-variables for the data
as a whole as well as by time period (1988–1998,
1999–2004 and 2005–2010).
Multivariable excess hazard modelling
We fitted flexible parametric excess hazard regression
models using stcrs [35] in order to estimate the excess
hazard ratio of death (i.e. death related to breast cancer)
within the first 5 years following diagnosis. This ap-
proach models the excess hazard on the log-hazard
scale, reducing computational intensity, and also allows
the estimation of both time-dependent and non-linear
covariable effects. We examined the mechanism giving
rise to missing values for the four variables within the
dataset with incomplete data (stage, smoking, alcohol
consumption and BMI) using logistic regression. In
order to account for the impact of these missing data in
the analysis, we implemented a five-fold multiple imput-
ation which was enough to obtain stable estimates and
variance. Imputation models were fitted separately for
each deprivation quintile to enable interactions to be
considered, and included all variables of interest. Missing
values for BMI were derived from a linear regression
model, stage from an ordered logistic model and
smoking and alcohol from multinomial regression. Esti-
mates were recombined using Rubin’s rules [36]. Initial
excess hazard models included, a priori, age, year of
diagnosis, deprivation and stage of disease at diagnosis.
We tested for non-linearity of each of these variables
using restricted cubic splines with 3 degrees of freedom
(2 internal knots) for age and year, and the ordered cat-
egorical form of the variable for deprivation using the
Stata sub-command mi test [36] (p-value < 0.05). Peri-
diagnostic variables which were observed to have a sig-
nificant association with both deprivation and net sur-
vival in the univariable analyses were included in turn,
first those relating individual health status, then individ-
ual consultation history in primary care. Models used all
disease stages, then were subsequently fitted only to
TNM stage I or II. Models were derived by follow-up
time in order to assess time-variance. Finally, we re-
peated all analyses restricting the cohort to diagnoses
2005–2010. We used precisely the same strategy, but in-
cluded in the model the number of days from diagnosis
to major breast surgery and the Charlson comorbidity
score derived from both CPRD and HES.
Results
Cohort & data linkage
Out of the 733,809 persons aged 16–99 years in England
recorded in the National Cancer Registry as having being
diagnosed with invasive breast cancer between 1 January
1988 and 31 December 2010, we analysed 21,802 women
for whom follow-up was complete up to 31 December
2014 (Fig. 1).
Descriptive analyses
A third of the women died on or before the end of follow-
up (Table 1). Women living in deprived areas were on
average 2 years older at diagnosis and less likely to be di-
agnosed in the screening age range 50–69 (p-value <
0.001). They were less frequently diagnosed with localised
(Stage I) disease (3.3% difference. 95% CI 1.4–5.2) and
much more likely to die during the study period (11.1%
difference, 95% CI 8.8–13.5). They were also more likely
to be recorded as current or ex-smokers (13.9% difference,
95% CI 11.6–16.3), non- or ex-drinkers (15.7% difference
95% CI 13.6–17.8), and have a recorded BMI above 24
(11.6% difference 95% CI 14.1–9.3). There was a very
strong linear association with pre-existing co-morbidities
and deprivation, with 82.2% of women living in the least
deprived areas having no pre-existing condition compared
to 70.7% of women living in the most deprived areas (dif-
ference 11.4 95%CI 9.6–13.5). Women in deprived areas
had a higher mean number of consultations overall (9.6 vs
8.5, p-value < 0.001), but a slightly lower number of
breast-related consultations compared with women living
in more affluent areas (0.4 fewer, 95% CI 0.1–0.8).
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Women living in the most deprived areas reported a simi-
lar number of breast symptoms to the GP prior to diagno-
sis than women living in the most affluent areas (53.9% vs
53.1% reporting at least 1). However, women living in
middle- to deprived areas (quintiles 3 and 4) reported
fewer (p-value < 0.01). The average time from symptom
report to diagnosis was longest amongst women in the
most affluent two quintiles (32.7 days) but not notably
shorter in any other group (30.7–32.4 days). These overall
patterns were similar in the data set restricted to diagno-
ses after 1 January 2005 (data not shown).
Using information from the HES database in order to
calculate the Charlson co-morbidity score for women
diagnosed after 2005 did not add much: 76.4% of the
cohort were identified as having no comorbidities with-
out HES data in comparison to 71.4% with (Table 1).
The distribution of co-morbidities overall was similar
with 17.5% having one significant co-morbidity. A
similarly strong association with deprivation was also
evident (p-values both < 0.001). Major breast surgery
was identified in 71.6% of the women in the cohort.
More deprived women tended to have surgery slightly
sooner overall (2.5 days earlier, 95% CI 0.4–4.7), and
were more likely to have surgery at the time of or before
diagnosis (11.3% in the most deprived vs 6.7% in the
least, difference 4.5, 95% CI 6.4–2.6).
Univariable survival analyses
Five-year net survival increased from 71.4% (95% CI
69.8–73.0) to 76.6% (95% CI 75.9–77.4) over study
period. Women living in more deprived localities had
lower survival, the difference between the least and most
deprived in survival (the survival ‘gap’) equal to 9% 5
years after diagnosis and 14% 10 years after diagnosis for
women diagnosed during the period 2005–2010 (the
post-screening era, Fig. 2a). Older women and those
Fig. 1 Schematic displaying numbers of persons registered in each database, data linkage proportion, numbers and percentages of eligible
persons excluded
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diagnosed at later stages displayed substantially poorer
outcomes (Fig. 2b, c). Smoking status was not associated
with net survival (Fig. 2e) and thus not included in the
multivariable modelling. Current drinkers had better
survival than non- or ex- drinkers whereas those with
greater numbers of comorbidities had increasingly worse
survival (Fig. 2f, d). Underweight and obese women
diagnosed up to 2004 had poorer outcomes compared to
those who were normal or overweight, but in the period
2005–2010 only underweight women experienced lower
net survival (Fig. 3). Those with either no consultations,
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Fig. 2 Net survival by patient demographics and individual health status: women diagnosed with breast cancer 1988–2010 and followed up to
31 December 2014
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to diagnosis had worse outcomes than those who had be-
tween 1 and 10 visits to the GP, as did those who had fewer
than two breast-related consultations, those whose time
from last symptom report to diagnosis was shorter, and
those whom received a single or no referral (Fig. 4a-e).
Among women diagnosed after 2005, survival was similar
irrespective of time from diagnosis to breast surgery, except
amongst women whose time to surgery was greater than 2
months or surgical status was missing amongst whom
survival was dramatically worse (Fig. 4f).
Multivariable excess hazard modelling
After accounting for age, year and stage at diagnosis, a single
unit increase in deprivation quintile was associated with a
significant 4.4% (95% CI 1.4–8.8) increase in excess mortality
due to breast cancer across all periods of follow-up time
(Fig. 5a) in the imputed data. Amongst women diagnosed
with stage I or II disease, the differential was greater (7.6,
95% CI 0.9–14.6) but of borderline significance. These
hazard ratios equate to a 17.5% (or 30.3% for stages I & II)
mortality differential between the most affluent and most
deprived groups. A similarly consistent linear association was
observed amongst women diagnosed 2005–2010 (Fig. 5b)
and for all the different age groups (data not shown).
The inclusion of co-variables relating to individual health
status, primary and secondary care had almost no impact on
the magnitude of the differential amongst those diagnosed
1988–2010 and minimal impact for those diagnosed 2005–
2010. Significant variables in the multivariable models were
restricted to alcohol intake, comorbidity and the number of
breast consultations. The number of breast symptoms re-
ported was significant for all women across the study period
but not for those diagnosed with early stage disease nor
those diagnosed after 2004. Time to breast surgery (available
only for women diagnosed after 2004) significantly improved
the fit but did not alter the magnitude of the association.
Women diagnosed with early stage disease between
2005 and 2010 who were living in areas categorised as
quintile 2 had lower excess mortality than women living
in quintiles 1, 3, 4 or 5 (Fig. 5c). Similar to the above,
only alcohol consumption and comorbidity improved fit
of these non-linear stage-adjusted models, but the num-
ber of consultations did not. Time to breast surgery




We have shown that individual health status at diag-
nosis and primary care consultation history vary by
deprivation status but do not explain socio-economic
differences in breast cancer survival in this cohort as
far as can be established from these data. A persistent
and consistent increase in deprivation-specific cancer
mortality was observed. Although the association did
not reach significance for women diagnosed most
recently, its magnitude was almost identical to that
for the period as a whole. The accuracy and com-
pleteness of some fields utilised in this study could be
improved. Nevertheless these data support the null
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Fig. 3 Net survival by body mass index (BMI) and period of
diagnosis: women diagnosed with breast cancer 1988–2010 and
followed up to 31 December 2014
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cancer survival are not primarily explained by pre-
existing individual health status and primary care
consultation history.
Strengths and limitations
We used a unique, national, population-based,
individually-linked database. This included three
separate measures of individual health status, a single
measure of pre-existing comorbidities and pre-
diagnostic consultation rate both overall and for breast
complaints specifically. We used the most up-to-date
survival analysis methodology [32] combined with
deprivation-specific estimates of background mortality,
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Fig. 4 Net survival by consultation history in the 18months prior to diagnosis: women diagnosed with breast cancer 1988–2010 and followed up
to 31 December 2014
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multiple peri-diagnostic factors upon the excess hazard
due to the disease [35].
We defined a woman’s deprivation category based
upon the characteristics of her local area. Consequently,
we have demonstrated the influence of ecologically-
measured deprivation, rather than of individual circum-
stances. Although LSOAs are designed to be as socially
homogenous as possible, it is probable that more
deprived individuals are distributed across the different
quintiles of ecological deprivation. Since personal
socio-economic data are not available in either the
CPRD or cancer registration databases evaluating the
direct impact of individual deprivation is not possible
in these data. The differentials we identify will are thus
likely to reflect the impact of both environmental (con-
textual) and individual deprivation. The extent to which
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Our database included a substantial proportion of
missing data, most importantly for stage, alcohol con-
sumption, and BMI. We accounted for these by multiple
imputation methods. Although we examined the likely
mechanisms giving rise to missing data, some residual
bias may still be present. For comorbidity, consultations,
referrals and symptoms there was no missing data sim-
ply because it was not possible to distinguish between,
for example, a patient with no pre-existing comorbidities
and one with unrecorded comorbidities. Further, our
measures of BMI, smoking and alcohol only capture a
part of the differences in underlying health status, nutri-
tion and physical activity. Residual confounding is thus
likely to be present. Our analysis of number of symp-
toms, referrals, comorbidities, and time to major breast
surgery assumed that ‘none recorded’ equated to ‘none
observed’. This is a limitation as some of these groupings
are likely to, in fact, represent persons who did report
symptoms, were referred or received surgery but for
whom this information is missing. In particular, it has
been noted that affluent women are more likely to
undergo surgery in the private sector, which is undetect-
able in the HES database [11]. We did not have very
detailed information on surgery (mastectomy, breast
conserving therapy) or other types of treatment received
(radiotherapy, chemotherapy, hormonal treatments)
which may potentially explain some of the differences
observed and could be included in further analyses for
periods in which these fields are more complete. For
example, the effectiveness of the surgery (experience of
surgeon, hospital, and neo-adjuvant therapies given) may
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Fig. 5 Excess hazard ratio of breast cancer death associated with increasing deprivationa: baseline and adjustedb in multivariable models fitted to
imputed data. a) Women diagnosed 1 January 1988–31 December 2010 followed up to 31 December 2014, all tumours and early stages. b)
Women diagnosed 1 January 2005–31 December 2010 followed up to 31 December 2014, all tumours. c) Women diagnosed 1 January 2005–31
December 2010 followed up to 31 December 2014, early stages. a Single unit increases derived from linear models are displayed with solid
symbols. Where the effect was found to be non-linear, (e.g. (c)) numbers displayed within the symbols correspond to the deprivation quintile
compared to the least deprived group (quintile 1). b Symbols are displayed only when the addition of the variable resulted in a significant
improvement in the model fit (p < 0.05). Variable descriptions (see text for full coding), Baseline: Model adjusted for age and year of diagnosis
only, Stage: Stage of disease at diagnosis, Alcohol: Drinking habits, BMI: Body Mass Index (kg/m2), Charlson: Charlson co-morbidity score, Consult.:
Number of consultations for any reason, Br. Consult.: Number of consultations for breast symptom, Br. Sympt: Number of breast symptoms
reported, Yrs prior diag: Number of days from last breast-related consultation to diagnosis, Referrals: Number of referrals for breast cancer, Time
surg.: Number of days from diagnosis to major breast surgery
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women by ethnicity in these analyses. Black women are
known to have lower breast survival than White or
South Asian women [9], in part due to more aggressive
tumours. We were unable to account for this but it is
unlikely to substantially bias our results since Black
women are a very small proportion (< 3%) of the overall
population [37].
Comparison with existing literature
These data are consistent with those we previously
reported which showed that neither individual health
status nor primary care consultation patterns explain
much of survival inequalities amongst women diagnosed
in the screening age range [20], as well as a notable ‘J’
shaped relationship between deprivation and survival for
women with early stage disease [38]. The data we
present here on stage I & II disease are also consistent
with our demonstration that socio-economic differen-
tials in net survival are present amongst women whose
tumour was screen-detected [10].
More deprived women in our study were no less likely
to consult their GP, in fact, they consulted slightly more
and reported a similar number of symptoms. This may
seem counter-intuitive given their more advanced dis-
ease at diagnosis and lower survival. However, it is con-
sistent with other data from the UK [39, 40], Denmark
[41] and Australia [42], as well as with an ecological
study of healthcare trusts in England which showed
symptom awareness for breast cancer was similar across
the socio-economic spectrum, although help-seeking be-
haviours were slightly lower in more deprived areas [43].
Breast cancer is characterised by especially short pre-
diagnosis presentation intervals [44] which may suggest
that the lack of association observed here between peri-
diagnostic factors and survival is unique to this malig-
nancy. However, peri-diagnostic consultation rates have
also been shown to be similar amongst colon cancer pa-
tients presenting as emergencies compared to non-
emergencies [45]. Since emergency presentation is much
more frequent amongst more deprived patients [46] this
lends weight to the interpretation that the lower cancer
survival experienced by more deprived cancer patients in
general are not primarily related to differential use or ac-
cess to primary care.
Implications for future research
This study has shown that the underlying reasons for
socio-economic differentials in cancer survival are elu-
sive but are not likely to fall exclusively in the peri-
diagnostic period. It is known that more deprived
women are disproportionately diagnosed with the most
aggressive, triple negative tumours which may partially
explain these observations [47, 48]. The fact that a
greater number of deprived women had major surgery at
the time of or prior to diagnosis may further suggest that
they are more frequently diagnosed via the emergency
route or opportunistically, but this is known to be rare
for breast cancer. Beyond this, timing of surgery did not
strongly influence survival except where it was > 2
months or missing, and was not strongly socio-
economically patterned (Table 1). However, it remains
the case that variations in treatment effectiveness, be-
yond the inclusion of major breast surgery and the tim-
ing of surgery [21], may have a significant role in
determining differentials in outcomes. Future investiga-
tions might examine differences in the types of hospital
patients to travel to [49], differential experience and re-
sources available in different centres [50], as well as the
types of treatment and follow-up patients are offered, or
opt to receive [51], and the timing of each of these
events.
Conclusions
We have demonstrated that socio-economic inequalities
in survival in these data cannot be explained by consult-
ation history or by pre-existing individual health status,
as measured in primary care. The absolute impact of the
differentials demonstrated here is relatively small for
women with breast cancer since the excess mortality rate
itself is now, mercifully, fairly low. However, it is prob-
able that these patterns are suggestive of a tendency to-
wards differential treatment effectiveness which has wide
ranging implications for cancers or other diseases with
socio-economically patterned outcomes where treatment
effectiveness is likely to be similarly differentiated. Since
reducing inequalities in premature mortality is a major
focus of current health policy in England [52], effort
should be made to develop a better understanding of the
causes and perpetuation of socio-economic health differ-
entials in secondary as well as primary care.
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